Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

PH284 increased feelings of hunger and was safe in patients with cancer cachexia, which results in significant weight loss.

Overusing nasal sprays can also lead to rebound congestion. If you have been using a nasal spray for three days and your symptoms aren’t any better, they’re getting worse, or you have serious side ...

Nasal tanning sprays are illegal and can cause serious side effects according to Australia's drug and medical device watchdog ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.